BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 22511114)

  • 1. [Management of advanced prostate cancer in elderly patients].
    Bompas E; Dedecker L
    Bull Cancer; 2012 Jul; 99 Suppl 1():S21-9. PubMed ID: 22511114
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of metastatic prostate cancer: the crucial role of geriatric assessment.
    Droz JP; Chaladaj A
    BJU Int; 2008 Mar; 101 Suppl 2():23-9. PubMed ID: 18307689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A pilot study of the vulnerable elders survey-13 compared with the comprehensive geriatric assessment for identifying disability in older patients with prostate cancer who receive androgen ablation.
    Mohile SG; Bylow K; Dale W; Dignam J; Martin K; Petrylak DP; Stadler WM; Rodin M
    Cancer; 2007 Feb; 109(4):802-10. PubMed ID: 17219443
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systemic therapeutic strategies for prostate cancer.
    Nelson WG
    Clin Adv Hematol Oncol; 2005 Aug; 3(8):619-21. PubMed ID: 16167046
    [No Abstract]   [Full Text] [Related]  

  • 5. Role of targeted therapy in the treatment of advanced prostate cancer.
    Fizazi K; Sternberg CN; Fitzpatrick JM; Watson RW; Tabesh M
    BJU Int; 2010 Mar; 105(6):748-67. PubMed ID: 20353536
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alkaline phosphatase level increase with initiation of hormone therapy for prostate cancer portends poor prognosis with rapid progression to bone metastases: a case report and review of the literature.
    Brown MW; Singh AK
    Clin Genitourin Cancer; 2006 Mar; 4(4):293-5. PubMed ID: 16729914
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Therapeutic guidelines in prostate cancer and role for bisphosphonates in bone metastasis].
    Miki T; Okihara K
    Nihon Rinsho; 2007 Nov; 65 Suppl 9():632-5. PubMed ID: 18161177
    [No Abstract]   [Full Text] [Related]  

  • 8. Understanding treatments for bone loss and bone metastases in patients with prostate cancer: a practical review and guide for the clinician.
    Higano CS
    Urol Clin North Am; 2004 May; 31(2):331-52. PubMed ID: 15123412
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nadir PSA level and time to PSA nadir following primary androgen deprivation therapy are the early survival predictors for prostate cancer patients with bone metastasis.
    Sasaki T; Onishi T; Hoshina A
    Prostate Cancer Prostatic Dis; 2011 Sep; 14(3):248-52. PubMed ID: 21502970
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multidisciplinary management of advanced prostate cancer: changing perspectives on referring patients and enhancing collaboration between oncologists and urologists in clinical trials.
    Carducci MA; Carroll PR
    Urology; 2005 May; 65(5 Suppl):18-22; discussion 22. PubMed ID: 15885275
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complete androgen blockade for the treatment of prostate cancer.
    Labrie F; Dupont A; Belanger A
    Important Adv Oncol; 1985; ():193-217. PubMed ID: 3916740
    [No Abstract]   [Full Text] [Related]  

  • 12. Comprehensive geriatric assessment for older patients with cancer.
    Extermann M; Hurria A
    J Clin Oncol; 2007 May; 25(14):1824-31. PubMed ID: 17488980
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preservation of bone health in prostate cancer.
    Lattouf JB; Saad F
    Curr Opin Support Palliat Care; 2007 Oct; 1(3):192-7. PubMed ID: 18685362
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate cancer in the elderly.
    Heinzer H; Steuber T
    Urol Oncol; 2009; 27(6):668-72. PubMed ID: 19879477
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recommendations from the Spanish Oncology Genitourinary Group for the treatment of patients with metastatic castration-resistant prostate cancer.
    Climent MA; Piulats JM; Sánchez-Hernández A; Arranz JÁ; Cassinello J; García-Donas J; González del Alba A; León-Mateos L; Mellado B; Méndez-Vidal MJ; Pérez-Valderrama B;
    Crit Rev Oncol Hematol; 2012 Sep; 83(3):341-52. PubMed ID: 22285697
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Locally advanced prostate cancer: effective treatments, but many adverse effects.
    Prescrire Int; 2013 Jan; 22(134):18-20, 22-3. PubMed ID: 23367679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early versus delayed androgen deprivation for prostate cancer: new fuel for an old debate.
    Ryan CJ; Small EJ
    J Clin Oncol; 2005 Nov; 23(32):8225-31. PubMed ID: 16278477
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Metastatic cancer of the prostate: course, diagnosis and therapeutic management].
    Wisard M; Gabellon S
    Rev Med Suisse Romande; 1995 Mar; 115(3):241-7. PubMed ID: 7777765
    [No Abstract]   [Full Text] [Related]  

  • 19. [Expert consensus for the diagnosis and treatment of bone metastasis from prostate cancer].
    Expert Group on the Diagnosis and Treatment of Bone Metastasis from Prostate Cancer
    Zhonghua Zhong Liu Za Zhi; 2010 May; 32(5):396-8. PubMed ID: 20723442
    [No Abstract]   [Full Text] [Related]  

  • 20. Management of Prostate Cancer in Elderly Patients: Recommendations of a Task Force of the International Society of Geriatric Oncology.
    Droz JP; Albrand G; Gillessen S; Hughes S; Mottet N; Oudard S; Payne H; Puts M; Zulian G; Balducci L; Aapro M
    Eur Urol; 2017 Oct; 72(4):521-531. PubMed ID: 28089304
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.